Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: J Immunol. 2017 Feb 22;198(7):2989–2999. doi: 10.4049/jimmunol.1602057

Figure 5. The pharmacological disruption of RPS19-C5aR1 interaction reduces Tregs and MDSC in tumors and periphery.

Figure 5

T reg cells in (A) tumors, *P= 0.0052, and (B) spleen, *P<0.0001, of Her2/neu transgenic NT-5 tumor-bearing mice treated with PBS or C5aR1 antagonist (C5aRA). MDSC in blood of NT-5 tumor-bearing (C) Her2/neu, *P=0.04 and (F) FVB wild-type mice, *P=0.0361 treated as in A, B. MDSC (CD11b+GR-1+) in tumors of (D) Her2/neu transgenic and (G) FVB wild-type mice treated as in A, B. Quantification of (E) D, *P=0.0025 and (H) G, *P=0.04. All statistical analyses by t-test. Scale bars 50 μm. Data are representative of at least three independent experiments with n=4–10.